These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 19183322

  • 1. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
    Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S.
    Diabet Med; 2008 Sep; 25(9):1129-31. PubMed ID: 19183322
    [No Abstract] [Full Text] [Related]

  • 2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 3. Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
    Joffe D.
    Am J Health Syst Pharm; 2010 Aug 15; 67(16):1326-36. PubMed ID: 20689121
    [Abstract] [Full Text] [Related]

  • 4. Liraglutide for type 2 diabetes mellitus.
    Kela R, Khunti K, Davies MJ.
    Expert Opin Biol Ther; 2011 Jul 15; 11(7):951-9. PubMed ID: 21563859
    [Abstract] [Full Text] [Related]

  • 5. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.
    Vilsbøll T.
    Expert Opin Investig Drugs; 2007 Feb 15; 16(2):231-7. PubMed ID: 17243943
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E, Jonker DM, Jacobsen LV, Ingwersen SH.
    J Clin Pharmacol; 2010 Aug 15; 50(8):886-94. PubMed ID: 20133507
    [Abstract] [Full Text] [Related]

  • 7. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M, Bouchard JR, Langer J.
    Clin Ther; 2013 Jun 15; 35(6):795-807. PubMed ID: 23642290
    [Abstract] [Full Text] [Related]

  • 8. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O.
    Diabetes; 2004 May 15; 53(5):1187-94. PubMed ID: 15111485
    [Abstract] [Full Text] [Related]

  • 9. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T.
    Postgrad Med; 2011 Sep 15; 123(5):239-47. PubMed ID: 21904107
    [Abstract] [Full Text] [Related]

  • 10. Liraglutide: from clinical trials to clinical practice.
    Gough SC.
    Diabetes Obes Metab; 2012 Apr 15; 14 Suppl 2():33-40. PubMed ID: 22405267
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y, Rosenblit PD.
    Curr Cardiol Rep; 2018 Sep 26; 20(11):113. PubMed ID: 30259238
    [Abstract] [Full Text] [Related]

  • 12. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, Zdravkovic M, Chapman IM.
    Diabetes Res Clin Pract; 2012 Aug 26; 97(2):258-66. PubMed ID: 22446097
    [Abstract] [Full Text] [Related]

  • 13. Treatment evaluation of liraglutide in type 2 diabetes.
    Kela R, Davies MJ.
    Expert Opin Biol Ther; 2012 Nov 26; 12(11):1551-6. PubMed ID: 22897447
    [Abstract] [Full Text] [Related]

  • 14. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study.
    Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S.
    Int J Clin Pharmacol Ther; 2008 Jun 26; 46(6):273-9. PubMed ID: 18541123
    [Abstract] [Full Text] [Related]

  • 15. Insulin degludec + liraglutide: a complementary combination.
    Stinkens K, Peene B, Mathieu C.
    Expert Opin Biol Ther; 2016 Sep 26; 16(9):1171-7. PubMed ID: 27484310
    [Abstract] [Full Text] [Related]

  • 16. The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment.
    Flint A, Kapitza C, Zdravkovic M.
    Diabetes Obes Metab; 2013 Oct 26; 15(10):958-62. PubMed ID: 23551925
    [Abstract] [Full Text] [Related]

  • 17. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M, Harris K, Brackett A.
    Ann Pharmacother; 2012 Jan 26; 46(1):68-78. PubMed ID: 22232377
    [Abstract] [Full Text] [Related]

  • 18. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T, Robbins DC, Williams SJ, Novikova L, Stehno-Bittel L.
    Pharmacol Res; 2013 Oct 26; 76():58-66. PubMed ID: 23891763
    [Abstract] [Full Text] [Related]

  • 19. Which incretin-based therapy for type 2 diabetes?
    Scheen AJ.
    Lancet; 2014 Oct 11; 384(9951):1325-7. PubMed ID: 25018117
    [No Abstract] [Full Text] [Related]

  • 20. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov 11; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.